Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy and peripheral stem cell transplantation may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy plus radiation therapy followed by peripheral stem cell transplantation in patients with refractory or recurrent non-Hodgkin's lymphoma.
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||HIGH DOSE CHEMORADIOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY REFRACTORY, RELAPSED AND POOR PROGNOSIS NON-HODGKIN'S LYMPHOMA|
|Study Start Date:||September 1995|
|Study Completion Date:||June 2003|
|Primary Completion Date:||June 2003 (Final data collection date for primary outcome measure)|
- Determine the efficacy of mobilization using filgrastim (G-CSF) with or without standard-dose ifosfamide, carboplatin, and etoposide (ICE), conditioning using ifosfamide and etoposide plus total body irradiation or high-dose ICE, and autologous peripheral blood stem cell (PBSC) transplantation as salvage therapy in patients with refractory, recurrent, or poor prognosis non-Hodgkin's lymphoma.
- Determine the efficacy of reinduction comprising ICE followed by autologous PBSC transplantation in these patients.
- Determine the ability of standard-dose ICE combined with hematopoietic growth factors to mobilize PBSC in these patients.
- Determine the contamination of PBSC by lymphoma cells in patients treated with this mobilization regimen.
- Determine the quality of life of patients treated with this regimen.
OUTLINE: Patients are stratified according to disease status (relapsed vs refractory), lymphoma grade (low vs intermediate vs high), number of extranodal sites, serum lactic dehydrogenase, performance status, age, and volume of disease.
Mobilization/harvest: Patients in first or greater complete remission (CR) are treated on regimen A, whereas patients with recurrent or refractory disease are treated on regimen B.
- Regimen A: Patients with poor prognosis intermediate-grade lymphoma (IGL) in first CR or IGL or low-grade lymphoma (LGL) in second or greater CR receive mobilization with filgrastim (G-CSF) subcutaneously (SC) daily on days 1-7. Autologous peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on days 5 and 6 (and day 7 if needed).
- Regimen B: Patients who are currently on the MSKCC standard dose salvage therapy protocol with ifosfamide, carboplatin, and etoposide (ICE) for recurrent or refractory IGL receive additional mobilization with G-CSF after completion of the last course of ICE. Patients with recurrent or refractory IGL, immunoblastic lymphoma, or LGL who have not previously received ifosfamide and are not currently on the MSKCC standard dose salvage protocol with ICE receive ifosfamide IV and carboplatin on day 2 and etoposide IV on days 1-3 (standard-dose ICE) followed by G-CSF SC. When blood counts recover, autologous PBSC are harvested and selected for CD34+ cells.
- Regimens A and B: If additional hematopoietic growth factors (HGFs) become available, they may be administered concurrently with G-CSF. If inadequate CD34+ cells are collected, then autologous bone marrow is harvested.
Conditioning: Patients who are under age 60 and have not received dose-limiting radiotherapy are treated on regimen C. Patients who are age 60 and over and patients who are under age 60 and have received dose-limiting radiotherapy are treated on regimen D.
- Regimen C: Patients undergo hyperfractionated total body irradiation twice a day on days -10 to -7 and ifosfamide IV over 1 hour followed by etoposide IV over 23 hours on days -6 to -2.
- Regimen D: Patients receive ifosfamide IV over 1 hour, followed by etoposide IV over 11 hours, followed by carboplatin IV over 1 hour, followed by etoposide IV over 11 hours on days -7 to -3 (high-dose ICE).
- Regimens C and D: Patients with residual or relapsed disease may undergo boost radiotherapy twice a day, 5 days a week, for 1-2 weeks before conditioning or after transplantation.
- Transplantation: PBSC or bone marrow is reinfused on day 0. Patients receive G-CSF SC every 12 hours beginning on day 1 and continuing until blood counts recover. If additional HGFs become available, they may be administered concurrently with G-CSF.
Quality of life is assessed at baseline and then at 6, 12, and 24 months after transplantation.
Patients are followed at 1 and 3 months, every 3 months through year 2, every 4 months through year 5, and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 80 patients (20 for regimen A and 60 for regimen B) will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002697
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Craig Moskowitz, MD||Memorial Sloan Kettering Cancer Center|